Our trading advice tool cross-verifies the current analyst consensus on Effector Therapeutics, assessing the company's growth potential in the present economic cycle. Approximately 22.0% of the company's shares are institutionally owned, including by insurance companies. The company reported a loss per share of 18.75 and has not issued any dividends in recent years. Effector Therapeutics underwent a 1:25 stock split on January 12, 2024.
Key Takeaways
As we delve into April's investment forecast, Effector Therapeutics (USA Stocks: EFTR) emerges as a potential game-changer in the Biotechnology industry. Despite a total risk alpha of
-0.39, indicating a potential loss, the company's day typical price of
$12.31 and an impressive accumulation distribution of
7.6K suggest a strong hype-driven investment opportunity. However, investors should be aware of the company's high mean deviation of
5.07, indicating a higher risk associated with this stock.
Use Technical Analysis to project Effector expected Price
Effector Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, delisted stock market cycles, or different charting patterns.
A focus of Effector Therapeutics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Effector Therapeutics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions.
More Info...Detailed Perspective On Effector Therapeutics
Net Loss for the year was (35.94
M) with loss before overhead, payroll, taxes, and interest of (19.76
M).
| 2021 | 2022 | 2023 | 2024 (projected) |
Interest Expense | 1.8M | 2.3M | 2.9M | 2.1M | Depreciation And Amortization | 24K | 53K | 47.7K | 45.3K |
Current Deferred Revenue Breakdown
Effector Therapeutics Current Deferred Revenue yearly trend continues to be relatively stable with very little volatility. Current Deferred Revenue is likely to drop to about 1.6
M. Current Deferred Revenue usually refers to revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. At this time, Effector Therapeutics' Current Deferred Revenue is relatively stable compared to the past year.
| 2010 | 1.98 Million |
| 2023 | 1.79 Million |
| 2024 | 1.59 Million |
As the old adage goes, "Don't put all your eggs in one basket," diversification is key when it comes to investing, and Effector Therapeutics (USA Stocks: EFTR) could be an intriguing choice for the adventurous investor. With a market capitalization of $40.56M and a robust cash and equivalents position of $41.04M, the company's
financial health appears solid. Despite a high probability of bankruptcy at 96%, the company's lead product candidate, Tomivosertib, is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer, which could be a game-changer for the firm. However, investors should be aware of the company's high downside deviation of 7.21 and maximum drawdown of 31.69, indicating potential volatility. In conclusion, while Effector Therapeutics presents certain risks, its potential upside of 10.92 suggests it could be a worthy addition to a diversified portfolio.
Another 3 percent spike for Effector Therapeutics
Despite a recent 3% rise in Effector Therapeutics' stock, investors should proceed with caution. The company's Sortino Ratio, a measure of risk-adjusted return, has increased to 0.07, indicating that the stock's return may not adequately compensate for the risk. This suggests a potential future drop in stock price. As of March 20, Effector Therapeutics has a Coefficient Of Variation of 1207.57, a mean deviation of 5.07, and a Downside Deviation of 7.21. Its
technical analysis, based on historical prices and volume patterns, can help predict future price direction. However, it's unclear if the firm will follow its historical price and volume momentum. Nineteen technical drivers for Effector Therapeutics have been analyzed and compared to its
competitors. Investors should confirm Effector Therapeutics' variance and the relationship between the value at risk and skewness to determine if the stock is priced favorably at its current price of $12.27 per share.
With a Jensen Alpha of 0.5781, it's recommended to verify Effector Therapeutics' current market performance to ensure its future sustainability. In conclusion, eFFECTOR Therapeutics (USA Stocks: EFTR) holds potential for investors with a high-risk tolerance and a focus on the biopharmaceutical sector. Currently, analysts have set the target price for EFTR at an estimated value of
$6.85, with potential upside reaching
$16.23. This suggests a significant potential for growth, if the company successfully navigates the development and commercialization of its lead product candidate, Tomivosertib. However, the valuation hype value standing at 13.03 against the market value of 12.27 indicates a certain degree of over-enthusiasm that investors should be wary of. The company's fiscal year end in December could bring more clarity on its financial stability. As of now, the company is recognized as a strong buy by analysts, but investors should conduct their due diligence, especially considering the potential downside price of $2.35. .
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Effector Therapeutics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]
